In this article, we will take a look at the 10 Fast-Growing AI Healthcare Companies to Watch Right Now. In this piece, we take a closer look at Hims & Hers Health Inc. (NYSE:HIMS) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.

Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.

Why Medicine Could Be AI’s Next Major Market

Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.

Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.

These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.

A Low Share Price Does Not Always Mean Cheap

A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.

The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.

Finding the Best AI Medicine Stocks

This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.

The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.

CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.

Our Methodology

For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.

10 Best Cheap AI Medicine Stocks to Buy Now

7. Hims & Hers Health Inc. (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE: HIMS) claims seventh place as a fast-growing consumer healthcare platform using technology and artificial intelligence to expand access to personalized treatment.

The company provides services across weight management, sexual health, hair care, dermatology, mental health and other consumer-health categories. Patients complete digital assessments, connect with healthcare professionals and receive treatments through an integrated online platform.

Artificial intelligence supports patient intake, treatment personalization, provider workflows and the company’s effort to serve a growing subscriber base without allowing administrative costs to rise at the same pace.

Second-quarter 2026 revenue reached approximately $753 million and exceeded market expectations. The company added more than 300,000 subscribers and raised its annual revenue forecast to between $3.1 billion and $3.3 billion.

Management is targeting at least $6.5 billion in annual revenue and $1.3 billion in adjusted EBITDA by 2030. If achieved, those targets would establish the platform as one of the largest digital health companies serving consumers directly.

Its growth strategy is not without complications. Expansion into branded weight-loss treatments and international markets has increased costs. Gross margin has declined for several consecutive quarters, and the company swung to a quarterly loss after previously reporting a profit.

The changing regulatory environment surrounding compounded weight-loss medicines is another major issue. Rules affecting semaglutide, peptides and other treatments can influence product availability, pricing and the economics of the weight-management business.

Hims & Hers Health, Inc. (NYSE: HIMS) ranks below the pure-play healthcare AI stocks because artificial intelligence is an important operating capability rather than the company’s primary product. The consumer brand, distribution platform and subscriber relationships remain the main commercial advantages.

Even so, the company’s scale and growth rate are difficult to ignore. If it can protect margins while expanding into additional medical categories, AI-powered personalization could help the business increase revenue per subscriber and improve long-term customer retention.

YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.